On the other hand, Fan et al. found that although a group of breast cancer patients (n = 7657) with RAD50 germline mutations (and without BRACA1/2 mutations) had unfavorable survival compared to other patients, these mutations were not necessarily associated with an increased risk of breast cancer because the frequency of the mutations was similar to control patients [93]. This evidence concerns the gene RAD50 and breast carcinoma.